Neurologic Disorders

Participants with lower bone mineral density at femoral neck more likely to develop all-cause dementia, Alzheimer disease during follow-up.

Tofersen is an investigational antisense medicine that reduces the synthesis of SOD1 protein production.

A multiple ascending dose study of a second generation formulation of ganaxolone is expected to begin in the second quarter of 2023.

ABBV-951 is a solution of levodopa and carbidopa prodrugs for continuous subcutaneous delivery.

Mean annualized relapse rate not different before vs after controlled ovarian stimulation.

On appeal, the court looked at a variety of cases to determine whether Dr K had a physician-patient relationship with Mr B based on the phone call between him and Dr M.

The approval was supported by data from the randomized, double-blind, placebo-controlled phase 3 LAVENDER study.

Global Alzheimer disease pathology lower in patients following these dietary patterns, specifically less beta-amyloid load

Limits on acetaminophen levels in combination opioid products linked to declines in liver injuries; Investigational Alzheimer disease drug fails to show efficacy; Bempedoic acid assessed for reducing major adverse cardiovascular events; Commercial blood test for suspected TBIs; Mammography regulations updated.

Solanezumab is a humanized monoclonal antibody designed to increase clearance of soluble amyloid beta (Aβ) from the brain by binding to aggregated forms of Aβ.

The table provided is a review of notable updates that occurred in February 2023 for investigational products in development.

Any vitamin D supplement exposure was associated with 40 percent lower dementia incidence

Eplontersen is an investigational ligand-conjugated antisense medicine.

Alinity i TBI lab test measures complementary biomarkers in blood plasma and serum that are tightly correlated to brain injury when elevated.

The sBLA is supported by data from the confirmatory phase 3 Clarity AD trial, which included patients with early Alzheimer disease.

Authors note a significantly reduced levodopa-induced dyskinesia and motor severity score opposite to the treated side

Skyclarys activates the Nrf2 pathway which is involved in the cellular response to oxidative stress.

To assess the potential risk, the FDA is working with manufacturers of neonatal incubators and evaluating data from their products.

No signs of higher risk seen for developmental disorders

Risk for all-cause, vascular dementia was increased with number of regularly used laxative types